Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy.

导出原文传递

翻译打印收藏纠错

第一作者： Jeffrey J,Jackson

第一单位： RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States.

作者： Jeffrey J,Jackson ^[1] ; Grant M,Shibuya ^[1] ; Buvana,Ravishankar ^[1] ; Lavanya,Adusumilli ^[1] ; Delia,Bradford ^[1] ; Dirk G,Brockstedt ^[1] ; Cyril,Bucher ^[1] ; Minna,Bui ^[1] ; Cynthia,Cho ^[1] ; Christoph,Colas ^[1] ; Gene,Cutler ^[1] ; Adrian,Dukes ^[1] ; Xinping,Han ^[1] ; Dennis X,Hu ^[1] ; Scott,Jacobson ^[1] ; Paul D,Kassner ^[1] ; George E,Katibah ^[1] ; Michelle Yoo Min,Ko ^[1] ; Urvi,Kolhatkar ^[1] ; Paul R,Leger ^[1] ; Anqi,Ma ^[1] ; Lisa,Marshall ^[1] ; Jack,Maung ^[1] ; Andrew A,Ng ^[1] ; Akinori,Okano ^[1] ; Deepa,Pookot ^[1] ; Daniel,Poon ^[1] ; Chandru,Ramana ^[1] ; Maureen K,Reilly ^[1] ; Omar,Robles ^[1] ; Jacob B,Schwarz ^[1] ; Anton A,Shakhmin ^[1] ; Hunter P,Shunatona ^[1] ; Raashi,Sreenivasan ^[1] ; Parcharee,Tivitmahaisoon ^[1] ; Mengshu,Xu ^[1] ; Thant,Zaw ^[1] ; David J,Wustrow ^[1] ; Mikhail,Zibinsky ^[1]

作者单位： RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States. ^[1]

主题词动物(Animals);血红素(Heme);小鼠(Mice);小鼠, 基因敲除(Mice, Knockout);T淋巴细胞(T-Lymphocytes);eIF-2激酶(eIF-2 Kinase)

DOI 10.1021/acs.jmedchem.2c00736

PMID 36127295

发布时间 2022-10-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交